Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Research material or Tryptamine or [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]]

Use the filters below to narrow your results.

generic:
brand:
None (132) · (none, never marketed) (1) · Flexeril (IR; brand discontinued in US, generic widely available), Amrix (ER) (1) · Lioresal (oral, intrathecal pump), Ozobax / Fleqsuvy (oral suspension), Gablofen (intrathecal), Lyvispah (oral granules) (1) · O-DSMT (1) · Robaxin (oral, injectable) (1) · Zanaflex (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (27) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · None (4) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)
uses:
None (133) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) · '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)
starting dose:
None (133) · 2 mg PO every 6-8 hours; titrate by 2-4 mg per dose every 1-4 days; maximum single dose 16 mg, maximum daily dose 36 mg (1) · IR 5 mg PO TID; titrate to 10 mg TID if needed. Amrix ER 15 mg PO once daily. Off-label insomnia / fibromyalgia: 5-10 mg PO at bedtime (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm (1) · Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump (1)
preparations:
None (133) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · IR tablets 5, 7.5, 10 mg; Amrix ER capsules 15, 30 mg (1) · Tablets 2, 4 mg; capsules 2, 4, 6 mg ('''capsules and tablets are not bioequivalent''': capsules slower with food; tablets faster on empty stomach) (1) · Tablets 5, 10, 20 mg; oral suspension 5 mg/5 mL (Ozobax, Fleqsuvy); intrathecal injection 50, 500, 1000, 2000 mcg/mL (Lioresal Intrathecal, Gablofen); oral granules (Lyvispah) (1) · Tablets 500, 750 mg; injection 100 mg/mL (1)
fda max:
None (133) · 30 mg/day (IR or ER) (1) · 36 mg/day in three divided doses; single dose maximum 16 mg (1) · 8 g/day (oral, short-term load); 6 g/day (chronic) (1) · 80 mg/day oral (higher off-label) (1) · N/A (never approved) (1)
routes:
None (133) · intramuscular (1) · intranasal; rectal and IV reported. (1) · intrathecal (via implanted infusion pump) (1) · intravenous (1) · Oral (5) · sublingual (1)
onset:
None (133) · 1-2 hours (oral) (1) · 30-60 minutes (1) · ~1 hour (1) · ~20–40 min PO; faster sublingual/intranasal. (1) · ~30 minutes (oral) (1)
duration:
None (133) · 12-24 hours (IR); 24 hours (Amrix ER) (1) · 3-6 hours per dose (1) · 4-6 hours (1) · 4-6 hours (oral, TID-QID dosing) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1)
halflife:
None (133) · 1-2 hours'"`UNIQ--ref-00000017-QINU`"' (1) · 18 hours (IR); 32-33 hours (ER)'"`UNIQ--ref-0000001A-QINU`"' (1) · 2.5 hours (short, requires TID-QID dosing)'"`UNIQ--ref-0000001D-QINU`"' (1) · 3-4 hours'"`UNIQ--ref-00000026-QINU`"' (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)
bioavailability:
None (133) · Not formally characterized in humans. (1) · ~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"' (1) · ~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"' (1) · ~40% (oral); food and formulation substantially alter the absorption profile'"`UNIQ--ref-0000001E-QINU`"' (1) · ~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"' (1)
pregnancy:
None (133) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (4)
legal:
None (134) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol among muscle-spasm options'"`UNIQ--ref-0000001F-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol which is Schedule IV'"`UNIQ--ref-00000019-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from the carisoprodol alternative for muscle spasm'"`UNIQ--ref-0000001C-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000028-QINU`"' (1)

Showing below up to 162 results in range #1 to #162.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"